4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 64 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $190,250 | -17.2% | 14,945 | +17.6% | 0.00% | – |
Q2 2023 | $229,724 | +11.1% | 12,713 | +5.7% | 0.00% | – |
Q1 2023 | $206,693 | -22.6% | 12,024 | 0.0% | 0.00% | – |
Q4 2022 | $267,053 | +163.1% | 12,024 | -4.7% | 0.00% | – |
Q3 2022 | $101,489 | +11.2% | 12,623 | -3.4% | 0.00% | – |
Q2 2022 | $91,257 | -48.8% | 13,074 | +11.0% | 0.00% | – |
Q1 2022 | $178,114 | -41.4% | 11,780 | -14.8% | 0.00% | – |
Q4 2021 | $304,000 | +1.0% | 13,834 | +23.8% | 0.00% | – |
Q3 2021 | $301,000 | – | 11,178 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |